Seaport Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Seaport Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Boston
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- SPTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0002042347
- EIN
- 99-2235719
Board of directors
-
Atlantic (Lux) S.a R.l. General · DirectorSince 2026
-
Atlantic GenPar (Lux) SCSp General · DirectorSince 2026
-
Daphne Zohar · Director · Chief Executive OfficerSince 2026
-
David E. Wheadon · DirectorSince 2026
-
Denice Torres · DirectorSince 2026
- Since 2026
-
Jason Pitts · DirectorSince 2026
-
Robert J. Hombach · DirectorSince 2026
-
Sandra E. Peterson · DirectorSince 2026
-
Sharon Mates · DirectorSince 2026
-
Steven M. Paul · DirectorSince 2026
Chief executives
Daphne Zohar
· Chief Executive Officer
Since April 2026
Board connections
9 of this board's directors also sit on 16 other boards.
- via Atlantic (Lux) S.a R.l. General and Atlantic GenPar (Lux) SCSp General
- via Atlantic (Lux) S.a R.l. General and Atlantic GenPar (Lux) SCSp General
- via James Healy and Steven M. Paul
- via James Healy
- via Sharon Mates
- via James Healy
- via Robert J. Hombach
- via James Healy
- via Denice Torres
- via Robert J. Hombach
- via Denice Torres
- via Robert J. Hombach
- via David E. Wheadon
- via Sandra E. Peterson
- via James Healy
- via David E. Wheadon
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $20,035,820
- 2 purchases by 2 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 22, 2026 | Robert J. Hombach Director | Open-market purchase | +13,000 | $18.14 | $235,820 |
| May 4, 2026 | PureTech Health plc 10% owner | Derivative conversion | +12,736,014 | — | — |
| May 4, 2026 | James Healy Director | Derivative conversion | +1,927,159 | — | — |
| May 4, 2026 | White Lauren Officer (Chief Financial Officer) | Derivative conversion | +6,702 | — | — |
| May 4, 2026 | Gladstein Lana Officer (General Counsel) | Derivative conversion | +33,515 | — | — |
| May 4, 2026 | Chen Michael Cunyuan Officer (Chief Scientific Officer) | Derivative conversion | +3,351 | — | — |
| May 4, 2026 | Denice Torres Director | Derivative conversion | +13,406 | — | — |
| May 4, 2026 | Steven M. Paul Director | Derivative conversion | +67,031 | — | — |
| May 4, 2026 | ARCH Venture Partners XII, L.P. 10% owner | Derivative conversion | +2,513,686 | — | — |
| May 4, 2026 | Loebel Antony Officer (Chief Medical Officer) | Derivative conversion | +20,109 | — | — |
| May 4, 2026 | PureTech Health plc 10% owner | Derivative conversion | +2,681,265 | — | — |
| May 4, 2026 | James Healy Director | Derivative conversion | +804,379 | — | — |
| May 4, 2026 | ARCH Venture Partners XII, L.P. 10% owner | Derivative conversion | +2,681,265 | — | — |
| May 4, 2026 | PureTech Health plc 10% owner | Derivative conversion | +965,255 | — | — |
| May 4, 2026 | ARCH Venture Partners XII, L.P. 10% owner | Open-market purchase | +1,100,000 | $18.00 | $19,800,000 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.